Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 11 studies | 30% ± 14% | |
peripheral blood | 8 studies | 23% ± 7% | |
kidney | 5 studies | 22% ± 5% | |
eye | 4 studies | 30% ± 21% | |
uterus | 4 studies | 32% ± 3% | |
breast | 4 studies | 19% ± 3% | |
esophagus | 3 studies | 37% ± 11% | |
brain | 3 studies | 22% ± 5% | |
skin | 3 studies | 26% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 97% | 20200.06 | 562 / 578 | 97% | 248.80 | 1126 / 1155 |
breast | 95% | 37791.10 | 436 / 459 | 98% | 452.40 | 1097 / 1118 |
kidney | 98% | 24357.40 | 87 / 89 | 95% | 274.13 | 852 / 901 |
bladder | 90% | 22043.19 | 19 / 21 | 93% | 235.71 | 468 / 504 |
skin | 80% | 24464.51 | 1448 / 1809 | 96% | 192.69 | 451 / 472 |
esophagus | 78% | 25177.99 | 1129 / 1445 | 97% | 194.45 | 178 / 183 |
prostate | 95% | 18029.89 | 232 / 245 | 79% | 138.09 | 397 / 502 |
adrenal gland | 98% | 15807.59 | 253 / 258 | 74% | 119.03 | 171 / 230 |
uterus | 78% | 9778.08 | 132 / 170 | 93% | 322.27 | 429 / 459 |
thymus | 80% | 15236.20 | 522 / 653 | 90% | 275.63 | 543 / 605 |
intestine | 71% | 8489.33 | 690 / 966 | 96% | 180.56 | 504 / 527 |
liver | 91% | 16434.96 | 205 / 226 | 74% | 102.13 | 302 / 406 |
ovary | 82% | 12240.49 | 147 / 180 | 73% | 93.81 | 314 / 430 |
pancreas | 50% | 4466.85 | 164 / 328 | 95% | 374.85 | 169 / 178 |
stomach | 43% | 4579.11 | 155 / 359 | 94% | 148.70 | 269 / 286 |
brain | 54% | 4383.11 | 1439 / 2642 | 47% | 51.91 | 328 / 705 |
ureter | 0% | 0 | 0 / 0 | 100% | 97.04 | 1 / 1 |
muscle | 97% | 23425.35 | 780 / 803 | 0% | 0 | 0 / 0 |
adipose | 96% | 26231.38 | 1157 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 359.89 | 43 / 45 |
blood vessel | 92% | 27657.38 | 1225 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 69% | 93.94 | 20 / 29 |
heart | 64% | 12352.21 | 551 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 58% | 9167.56 | 541 / 929 | 0% | 0 | 0 / 0 |
spleen | 34% | 2626.82 | 83 / 241 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 18% | 12.96 | 14 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0043433 | Biological process | negative regulation of DNA-binding transcription factor activity |
GO_0032922 | Biological process | circadian regulation of gene expression |
GO_0007623 | Biological process | circadian rhythm |
GO_0042752 | Biological process | regulation of circadian rhythm |
GO_0006355 | Biological process | regulation of DNA-templated transcription |
GO_0009952 | Biological process | anterior/posterior pattern specification |
GO_0043153 | Biological process | entrainment of circadian clock by photoperiod |
GO_0050767 | Biological process | regulation of neurogenesis |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0016604 | Cellular component | nuclear body |
GO_0005737 | Cellular component | cytoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0043425 | Molecular function | bHLH transcription factor binding |
GO_0019904 | Molecular function | protein domain specific binding |
GO_0001227 | Molecular function | DNA-binding transcription repressor activity, RNA polymerase II-specific |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_1990837 | Molecular function | sequence-specific double-stranded DNA binding |
GO_0061629 | Molecular function | RNA polymerase II-specific DNA-binding transcription factor binding |
GO_0003700 | Molecular function | DNA-binding transcription factor activity |
GO_0046982 | Molecular function | protein heterodimerization activity |
GO_0070888 | Molecular function | E-box binding |
GO_0043426 | Molecular function | MRF binding |
GO_0005515 | Molecular function | protein binding |
Gene name | BHLHE40 |
Protein name | Class E basic helix-loop-helix protein 40 (bHLHe40) (Class B basic helix-loop-helix protein 2) (bHLHb2) (Differentially expressed in chondrocytes protein 1) (DEC1) (Enhancer-of-split and hairy-related protein 2) (SHARP-2) (Stimulated by retinoic acid gene 13 protein) |
Synonyms | DEC1 BHLHB2 STRA13 SHARP2 |
Description | FUNCTION: Transcriptional repressor involved in the regulation of the circadian rhythm by negatively regulating the activity of the clock genes and clock-controlled genes . Acts as the negative limb of a novel autoregulatory feedback loop (DEC loop) which differs from the one formed by the PER and CRY transcriptional repressors (PER/CRY loop) . Both these loops are interlocked as it represses the expression of PER1/2 and in turn is repressed by PER1/2 and CRY1/2 . Represses the activity of the circadian transcriptional activator: CLOCK-BMAL1|BMAL2 heterodimer by competing for the binding to E-box elements (5'-CACGTG-3') found within the promoters of its target genes . Negatively regulates its own expression and the expression of DBP and BHLHE41/DEC2 . Acts as a corepressor of RXR and the RXR-LXR heterodimers and represses the ligand-induced RXRA and NR1H3/LXRA transactivation activity . May be involved in the regulation of chondrocyte differentiation via the cAMP pathway . Represses the transcription of NR0B2 and attentuates the transactivation of NR0B2 by the CLOCK-BMAL1 complex . Drives the circadian rhythm of blood pressure through transcriptional repression of ATP1B1 in the cardiovascular system . . |
Accessions | O14503 ENST00000256495.4 |